Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
2348 On Other Exchanges
Symbol
Exchange
2348 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

dawnrays pharmaceutical hold (2348) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DAWNRAYS PHARMACEUTICAL HOLD (2348)

Related News

No related news articles were found.

dawnrays pharmaceutical hold (2348) Related Businessweek News

No Related Businessweek News Found

dawnrays pharmaceutical hold (2348) Details

Dawnrays Pharmaceutical (Holdings) Limited, an investment holding company, develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China and internationally. The company operates in two segments, Intermediates and Bulk Medicines, and Finished Drugs. It offers cephalosporin antibiotics cover intermediates, bulk medicines, and powder for injections; and specific medicines covering therapeutic areas for anti-HBV, anti-allergic, cardiovascular system, digestive system, urinary system, and endocrine system with dosage forms of tablets, capsules, and granules. The company was founded in 1995 and is headquartered in Wanchai, Hong Kong. Dawnrays Pharmaceutical (Holdings) Limited is a subsidiary of Fortune United Group Limited.

1,008 Employees
Last Reported Date: 08/18/15
Founded in 1995

dawnrays pharmaceutical hold (2348) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: CNY867.0K
Co-Founder and Executive Director
Total Annual Compensation: CNY534.0K
Executive Director
Total Annual Compensation: CNY534.0K
Compensation as of Fiscal Year 2014.

dawnrays pharmaceutical hold (2348) Key Developments

Dawnrays Pharmaceutical Holdings Ltd. Declares Interim Dividend for the Six Months of 2015

Dawnrays Pharmaceutical Holdings Ltd. declared an interim dividend for the year ending 31 December 2015, at HKD 0.030 per share, amounting to a total sum of approximately HKD 24,130,000.

Dawnrays Pharmaceutical Holdings Ltd. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Dawnrays Pharmaceutical Holdings Ltd. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the period, the company reported revenue of RMB 488,755,000 against RMB 409,884,000 a year ago. Profit before tax was RMB 191,698,000 against RMB 130,094,000 a year ago. Profit attributable to owners of the parent was RMB 154,260,000 against RMB 101,784,000 a year ago. Diluted earnings per share attributable to ordinary equity holders of the parent were RMB 0.1914 against RMB 0.1262 a year ago. The increase in profit was mainly because sales of the Group's system specific medicines recorded more satisfactory growth than that for the same period of 2014. Such increase in profit was mainly because additional profits arose from the relatively fast growth in sales of system specific medicines.

Dawnrays Pharmaceutical Holdings Ltd. to Report First Half, 2015 Results on Aug 18, 2015

Dawnrays Pharmaceutical Holdings Ltd. announced that they will report first half, 2015 results on Aug 18, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
2348:HK $6.45 HKD +0.28

2348 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 2348.
View Industry Companies
 

Industry Analysis

2348

Industry Average

Valuation 2348 Industry Range
Price/Earnings 15.5x
Price/Sales 4.6x
Price/Book 3.0x
Price/Cash Flow 15.4x
TEV/Sales 3.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DAWNRAYS PHARMACEUTICAL HOLD, please visit www.dawnrays.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.